Symptomatic obstructive sleep apnea (OSA) affects 2% of women and 4% of men, but the prevalence of asymptomatic OSA is significantly higher. Several ophthalmic conditions are associated with OSA, including floppy eyelid syndrome, glaucoma, nonarteritic anterior ischemic optic neuropathy, papilledema, keratoconus, and central serous chorioretinopathy. The purpose of this review is to provide primary care physicians with a general knowledge of the signs, symptoms, and management of the ophthalmic diseases associated with OSA.
Obstructive sleep apnea (OSA) has been shown to be associated with various ophthalmic diseases. It is therefore important for primary care physicians who treat patients with OSA to be aware of these diseases so that appropriate ophthalmic care can be referred, if applicable. The prevalence of symptomatic OSA among various ethnic groups and geographic locations is approximately 4% in men and 2% in women.1 The true prevalence of OSA may be much higher; one study found that 24% of men and 9% of women had OSA diagnosed on laboratory polysomnography.1 In a 2014 study,2 26 of 30 patients with OSA had some form of ocular involvement, and the 4 that did not were classified as having mild OSA. Ophthalmic diseases that may be associated with OSA include floppy eyelid syndrome (FES), chronic eye irritation, glaucoma, nonarteritic anterior ischemic optic neuropathy (NAION), papilledema, keratoconus, and central serous chorioretinopathy (CSCR). In addition, OSA may cause complications in patients taking anti–vascular endothelial growth factor (anti-VEGF) agents for retinal diseases.
Obstructive sleep apnea is a multisystem disease and is associated with an increased risk of hypertension, cardiovascular disease, diabetes, and changes in neurocognitive function.1 The occurrence of ophthalmic disease as a comorbidity in patients with OSA lends itself to the concept of holism and the tenets of osteopathic medicine.3,4 Osteopathic physicians are well situated to address the needs of patients with OSA by integrating the total human organism rather than a summation of its parts. In addition, a patient-oriented and integrated medical team effort brings together both generalists and specialists to deliver optimal patient care. In the present article, we describe the signs, symptoms, and management of ophthalmic diseases associated with OSA.
Floppy Eyelid Syndrome
A condition where the upper eyelid becomes highly elastic and is easily everted or folded upward (Figure 1), FES is often accompanied by papillary conjunctivitis, eyelid edema, and ocular discomfort. The prevalence of OSA in patients with FES may be as high as 96%.5 However, the prevalence of FES in patients with OSA has been reported to be anywhere between 2% and 33%.5,6 Thus, most patients with FES have OSA, but fewer patients with OSA have FES. Of patients with FES, approximately 86% are male and 88% are obese.6 Although OSA is the most frequent systemic disease associated with FES, it is unclear if the relationship is causative.5 Floppy eyelid syndrome is also associated with diabetes, hypertension, hyperlipidemia, and ischemic heart disease.5,6 All of these systemic diseases are frequently associated with obesity, making it complicated to determine the causative factor.5,6
Some of the ocular manifestations of FES are the result of the cornea being exposed at night, leading to punctate epithelial erosions, dry eyes, exposure keratopathy, corneal scarring, and neovascularization or ulceration, which may, rarely, lead to a microbial infection or corneal perforation.5-7 Keratoconus, a progressive condition involving corneal thinning and irregular astigmatism, has been associated with FES.5,7 Eyelid disorders have also been associated with FES, including eyelid edema, dermatochalasis (droopy upper eyelids with redundant skin), blepharitis, meibomianitis (inflammation of the eyelid margins and meibomian glands), ectropion (lower eyelid turns outwards away from the eyeball), eyelash ptosis (eyelashes point down instead of curling upward (Figure 2), and trichiasis (eyelashes point toward the eye and cause mechanical irritation).5-7 Chronic papillary conjunctivitis is often present in patients with FES, and other types of conjunctivitis may occur.5
Obstructive sleep apnea is the most frequent systemic disease that is associated with FES.
The upper eyelid in FES is easily everted. Whereas a normal eyelid stays relatively apposed to the globe when pulled upward, a floppy eyelid will evert, exposing the conjunctival inner lining of the eyelid. This sign has been reported to have been seen by sleep partners while the patient is asleep, and sometimes the patient notices it upon waking.7 Upper eyelid laxity can be quantified by measuring the vertical eyelid pull. This method involves measuring the difference between the eyelid at resting position and at maximal manual displacement superiorly. Normal eyelids measure approximately 5 to 10 mm; in FES, the eyelids measure 15 to 25 mm.7
In patients with chronic obstructive sleep apnea (OSA), floppy eyelid syndrome is thought to be caused by mechanical trauma to the eyelids during sleep. It can be associated with many eyelid and corneal pathologic conditions, ranging from dry eyes to corneal ulceration and infection.
Glaucoma, ischemic optic neuropathy, papilledema, keratoconus, and retinal diseases are more prevalent in patients with OSA than in those without OSA.
Glaucoma is a slowly progressive degeneration of the optic nerve that does not cause symptoms until late in the disease process; thus, patients should be screened regularly for signs of glaucoma.
Ischemic optic neuropathy is an ischemic injury to the optic nerve that presents as sudden vision loss in one eye. Permanent vision loss can also occur in the fellow eye.
Papilledema is bilateral swelling of the optic nerves due to increased intracranial pressure.
Keratoconus is a bilateral progressive thinning of the cornea. It causes irregular astigmatism and can cause vision loss if severe. Keratoconus may have an association with floppy eyelid syndrome.
Retinal diseases, such as central serous chorioretinopathy or macular edema, can cause vision loss if severe and untreated. However, patients with OSA may respond poorly to anti-VEGF therapy for diabetic macular edema or wet macular degeneration.
Several possible mechanisms for FES have been proposed. The mechanical theory suggests that mechanical trauma caused by the eyelids rubbing against the pillows at night causes floppy eyelids and the associated papillary conjunctivitis.5,7 This theory is supported by the evidence that FES occurs on the side the patient prefers to sleep on or occurs bilaterally if the patient alternates sleeping sides.5,7 However, this correlation is not perfect. Eye rubbing, another form of mechanical trauma, is thought to be associated with FES and has also been implicated in keratoconus.5 Another theory suggests that in patients with OSA, the upper eyelid becomes ischemic while the patient is laying on his or her side. In this theory, sudden reperfusion as the patient awakens causes damage to the tarsal plate and triggers a papillary reaction.5,7 However, to our knowledge, no clear evidence exists to support this idea. Other theories include poor eyelid-to-globe apposition, inflammation of the meibomian glands in the eyelid, Demodex eyelid infestation, or a genetic disease.5
The eyelid edema seen in patients with FES results from tissue fluid and plasma protein accumulation secondary to inflammation, mechanical trauma, and system dysfunction, causing an imbalance in the lymphaticovenous homeostasis.8 When venous or lymphatic congestion is involved, osteopathic manipulative treatment techniques that promote venous and lymphatic drainage from the head and neck may offer symptomatic relief. Superficial lymphatic drainage techniques such as effleurage to the face are directed at lymphatic flow as it leaves the eyelids and enters the lymphatics of the skin.8 The management of cervical and thoracic somatic dysfunctions can address restrictions that prevent proper lymphatic drainage from the head and neck, which may decrease periorbital edema.9 Additional conservative treatments include wearing a plastic or metal shield at night and using ocular lubricants or artificial tears.5,7 However, FES is often resistant to topical treatment.6,7 Patients with FES often show improvement with treatments for patients with OSA.7 Various surgical techniques have been described for tightening the upper eyelid, which are successful for most patients.5
The mechanism for glaucoma is unknown; theories generally involve mechanical damage due to increased pressure or decreased vascular perfusion to the optic nerve. Glaucoma is a disease characterized by progressive thinning of the nerve fibers of the optic nerve that can lead to vision loss. Often there is an increase in intraocular pressure (IOP), but if the IOP is normal, the condition is termed normal-tension glaucoma. If the anterior chamber angle is narrow, decreasing aqueous outflow and increasing IOP, the condition is termed narrow-angle glaucoma. If the anterior chamber is not narrow, the condition is termed open-angle glaucoma. Glaucoma is asymptomatic until late in the disease process; thus, it is important for patients to be screened regularly by an eye care professional. Currently, no cure for glaucoma exists, and treatment involves lowering the IOP, which may help to slow progression of the disease.
Many studies have found a link between open-angle glaucoma and OSA,10,11 although some of these studies failed to find a statistically significant relationship.12,13 These studies12,13 showed that glaucoma is more prevalent in patients with OSA, particularly in severe cases of OSA. The reverse has also been shown. Patients with glaucoma, particularly normal-tension glaucoma, have a higher prevalence of OSA than the general population.12 The reported prevalence of glaucoma in patients with OSA ranges from 2% to 27%, whereas the presence of glaucoma in the general population is approximately 2% to 3%.12 One study14 found that patients with FES may be more likely to have glaucoma.
Glaucoma is a sight-threatening disease; thus, it is imperative that patients with risk factors for glaucoma are monitored regularly.
Patients with OSA were found to be more likely than the general population to have many of the diagnostic criteria for glaucoma, including increased IOP, decreased thickness of the retinal nerve fiber layer, glaucomatous optic nerve changes, and abnormal visual field indices (Figure 3).12 This study12 found no statistically significant difference in ocular blood flow as measured by orbital Doppler ultrasonography between patients with OSA and the general population. Obstructive sleep apnea has been shown to cause a decrease in IOP at night, and continuous positive airway pressure (CPAP) machine use has been shown to increase IOP at night.15 Normally, IOP is highest during slow-wave sleep and lowest during rapid eye movement sleep.15 Obstructive sleep apnea tends to decrease the amount of time spent in slow-wave sleep, theoretically producing a lower IOP. Restoration of normal breathing patterns with CPAP therapy elevated IOP to a normal pattern in 12 patients.15 Pepin et al15 reported reestablishment of normal IOP and blood pressure rhythm with CPAP, citing a likely positive effect of glaucoma treatment due to improvements in underlying vascular variables.
The pathogenesis of glaucoma in patients with OSA is likely a combination of mechanical and vascular factors. Mechanical factors include increased IOP at night due to a supine sleeping position or an increase in episcleral venous pressure in obese patients.16 Vascular factors include periods of hypoxia followed by oxidative stress during reperfusion.12 This combination of mechanical and vascular stress may lead to damage to the optic nerve and subsequent glaucoma diagnosis.
Glaucoma is a sight-threatening disease; thus, it is imperative that patients with risk factors for glaucoma be monitored regularly. Although the relationship between OSA and glaucoma is not yet fully understood, it is generally accepted that there is an association between the 2, especially in patients with severe OSA. Glaucoma management may include topical drops to lower IOP or various laser or surgical techniques also aimed at lowering IOP.
Nonarteritic Anterior Ischemic Optic Neuropathy
An ischemic injury to the optic nerve not related to arteritis, NAION occurs when hypoperfusion to the optic nerve causes sudden painless vision loss in one eye, edema of the optic disc, and a relative afferent pupillary defect (Figure 4).17 Often a defect exists in the visual field of the affected eye. The loss of vision may occur when a patient wakes in the morning.18 Patients with systemic diseases that can affect perfusion to the optic nerve, such as diabetes, hypertension, atherosclerosis, and OSA, may have a higher risk of NAION.17 A small optic nerve with a small optic cup is also a risk factor for NAION. This characteristic is often observed in the unaffected eye but presumed to be present in both eyes.17 Visual acuity may improve with time but remains poor in approximately two-thirds of patients.17
Patients with OSA have been shown to have a greater prevalence of NAION than the general population.18 The presence of OSA in patients with NAION may be as high as 71% to 89%,18,19 and NAION is 16% more likely to develop in patients with OSA than in patients without OSA.14 Several theories exist as to why OSA may cause patients to be susceptible to NAION. One theory suggests that nocturnal hypoxia in OSA directly causes nerve damage.18 Another theory predicts that OSA causes vascular dysregulation of the nerve due to oxidative stress and other factors.18 A different theory suggests that damage to the optic nerve is caused by an increase in intracranial pressure (ICP) during apneas.18 The pathophysiologic mechanism of NAION in OSA may be due to a combination of factors described in these theories.
Nonarteritic anterior ischemic optic neuropathy is more prevalent in patients with OSA than in the general population.
Nonarteritic anterior ischemic optic neuropathy is a serious condition that causes permanent vision loss and can occur in the fellow eye. Use of CPAP machines may decrease the risk of NAION developing in the fellow eye.19 Management of NAION involves controlling risk factors for recurrence, including management of any systemic disease involved. Orbital decompression surgery and intravitreal injections of steroids or anti-VEGF agents have not been shown to be effective treatment modalities.18,20
The relationship between papilledema and OSA has not been as extensively researched as have FES, glaucoma, and NAION. Conflicting findings have been reported. Some case reports have demonstrated a positive correlation,17 and other studies have not.21,22 Papilledema is bilateral swelling of the optic disc (Figure 5). When the disc edema is caused by an increase in ICP and not by any other mechanism, it is termed pseudotumor cerebri, or idiopathic intracranial hypertension (IIH). Patients with IIH are often obese, as are patients with OSA.
During sleep, patients with OSA have been shown to have increases in their ICP that correspond to their episodes of apnea.23 For some patients, these increases can cause papilledema.21 Owing to the lack of oxygen in the blood during apnea episodes, patients with OSA may be more at risk for vision loss than patients with IIH and without OSA.21 Multiple mechanisms are likely involved with papilledema in patients with OSA. Increased resistance in the jugular veins, leading to increased ICP, may be caused by a combination of mouth breathing, head posture, and obesity.23 Intracranial edema in patients with OSA may be caused by neuroexcitotoxicity, disruption of the blood-brain barrier, or hypercoaguability.23
Usually, IIH improves or resolves with weight loss. Complete resolution has been shown with a weight loss of just 6%.24 An additional management method for IIH is diuretic prescription to decrease ICP (oral acetazolamide or another diuretic). Sometimes surgical methods are indicated, such as a lumboperitoneal shunt or optic nerve sheath fenestration. Patients with OSA and papilledema may have resolution of the papilledema with management of the OSA, including CPAP machine use or tracheostomy.21,25
In patients with keratoconus, the central cornea protrudes outward, forming the appearance of a cone. Keratoconus is a bilateral condition characterized by progressive thinning of the cornea and high irregular astigmatism. Studies have shown that patients with keratoconus are more likely to have OSA than the general population.26 Approximately 18% to 20% of patients with keratoconus have OSA, and many more patients with keratoconus may be at risk for OSA.27,28 Male patients with keratoconus who have a high body mass index (24.5-43.22) or a family history of OSA are more likely to have OSA.28 Additionally, FES is more common in patients with keratoconus than in the general population.29 When obesity was eliminated as a confounding factor, nonobese patients with keratoconus had no increased incidence of OSA than the general population.25
The mechanism for keratoconus in patients with OSA is not well understood. Obesity may have a role in both conditions. A common theory is that eye rubbing or manipulation during sleep causes mechanical damage to the cornea.26 The mechanical theory of FES suggests that rubbing of the eyelid and cornea against the pillow at night by OSA patients causes FES and its associated corneal conditions, including keratoconus. Sleeping position in patients with OSA may contribute to the development of keratoconus, but it has not been well researched.27 Another theory speculates that an inflammatory process resulting from increased matrix metalloproteinases may be involved in the pathogenesis of both OSA and keratoconus.27,29
Keratoconus is a progressive ophthalmic condition that can result in vision loss and severe corneal edema in extreme cases. The condition is treated in a variety of ways depending on patient characteristics. Refractive error is often better corrected with contact lenses, including scleral contact lenses, rigid gas permeable contact lenses, or hybrid hard lenses with a peripheral soft lens skirt. Surgical options include corneal transplant, implantable plastic rings, or corneal collagen crosslinking.
Central Serous Chorioretinopathy
Also called central serous retinopathy, CSCR is a condition in which a serous detachment of the neurosensory retina develops at the macula (Figure 6). Patients with CSCR may report distorted vision or have decreased visual acuity in the 20/30 to 20/60 range.30 It may be caused by increased permeability in the choriocapillaris, a vascular layer of the choroid, and subsequent damage to the retinal pigment epithelium.30 Central serous chorioretinopathy has been associated with increased endogenous or exogenous cortisol, which occurs with Cushing syndrome, corticosteroid therapy, pregnancy, and stress, as well as in patients with a “type A” personality.30 This condition is more common in men.30
Approximately two-thirds of patients with CSCR have OSA.31 One study found that when controlling for obesity, no statistically significant difference was found in the prevalence of OSA in patients with CSCR than in the general population.32 Thus, there seems to be a strong link between CSCR and OSA, but this correlation may result from the common factor of obesity.
One possible mechanism for the increased prevalence of CSCR in patients with OSA is increased oxidative stress. Oxidative stress can cause endothelial cell damage and vasoconstriction, both of which may be related to the pathogenesis of CSCR.31 Ischemia may cause increased permeability of the choriocapillaris.31 Another theory involves abnormalities of blood coagulation.31
Although usually self-limiting, CSCR recurs in up to 50% of patients.30 If chronic, CSCR can lead to vision loss over time. Treatment for CSCR usually involves monitoring and decreasing risk factors. In chronic or recurrent cases, therapy may include laser treatment, intravitreal anti-VEGF agents, or systemic medications, such as aldosterone antagonists, β blockers, and carbonic anhydrase inhibitors.30
Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration, and Anti-VEGF
In patients with diabetes, retinal thickening and fluid accumulation at the macula is called diabetic macular edema (DME) (Figure 7). One study found an increase in the prevalence of DME in patients with OSA.33 This association may be a result of periodic increases in blood pressure in patients with OSA, causing fluid leakage at the macula.33 Focal laser treatment may be used, but DME is more commonly managed with anti-VEGF agents.
More recently, a link has been found between the poor response to anti-VEGF therapy for DME or neovascular age-related macular degeneration (ARMD) in the presence of OSA.34,35 Vascular endothelial growth factor is involved in the pathogenesis of both DME and neovascular ARMD, causing growth of new blood vessels, increased vascular permeability, and subsequent vessel leakage.34 Intravitreal injections of anti-VEGF agents are the primary treatment used for patients with DME and neovascular ARMD. Resistance to anti-VEGF treatment in patients with OSA may be due to increased VEGF secretion during episodes of hypoxia.34 Oxidative stress, inflammation, and endothelial cell dysfunction all cause increased VEGF secretion.34 Management of OSA with CPAP therapy has been found to promote a positive response to anti-VEGF treatment, with a decrease in central retinal thickness and subretinal fluid and a need for fewer anti-VEGF injections.35
The various ophthalmic diseases associated with OSA may cause patient discomfort or vision loss over time. To provide the highest level of care and improve patient quality of life, physicians should be aware of these associations and should refer patients with OSA for ophthalmic care. Management of OSA and its associated conditions should involve the patients’ primary care physician as well as ophthalmologists and other specialists, when applicable. Management should focus on improving ocular comfort and decreasing the risk of vision loss.
1. Lee W , NagubadiS, KrygerMH, MokhlesiB. Epidemiology of obstructive sleep apnea: a population-based perspective. Expert Rev Respir Med.2008;2(3):349-364. doi:10.1586/17476318.104.22.1689.10.1586/17476322.214.171.1249Search in Google Scholar PubMed PubMed Central
2. Mohamed EE , MassoudTH. Effect of sleep related breathing disorders on ocular function. Egypt J Chest Dis Tuberc.2014;63(3):663-669. doi:10.1016/j.ejcdt.2014.02.010.10.1016/j.ejcdt.2014.02.010Search in Google Scholar
3. Greenman PE. Principles of Manual Medicine . 2nd ed.Philadelphia, PA: Lippincott Williams & Wilkins; 1996:3-11.Search in Google Scholar
4. Tenets of osteopathic medicine. American Osteopathic Association website. http://www.osteopathic.org/inside-aoa/about/leadership/Pages/tenets-of-osteopathic-medicine.aspx. Accessed June 17, 2018.Search in Google Scholar
5. Ezra DG , BeaconsfieldM, CollinR. Floppy eyelid syndrome: stretching the limits. Surv Ophthalmol.2010;55(1):35-46. doi:10.1016/j.survophthal.2009.02.025.10.1016/j.survophthal.2009.02.025Search in Google Scholar PubMed
6. Leibovitch I , SelvaD. Floppy eyelid syndrome: clinical features and the association with obstructive sleep apnea. Sleep Med.2005;7(2):117-122. doi:10.1016/j.sleep.2005.07.001.10.1016/j.sleep.2005.07.001Search in Google Scholar PubMed
7. Moscato EE , Jian-AmadoA. Floppy eyelid syndrome. Compr Ophthalmol Update. 2007;8(2):59-65.Search in Google Scholar
8. Kuchera ML. Lymphatics approach. In: ChilaA, executive ed.Foundations of Osteopathic Medicine. 3rd ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2011:786-808.Search in Google Scholar
9. Apozuanski TE , Abu-SbaihR, TerzellaMJ, YaoS. Resolution of dacryostenosis after osteopathic manipulative treatment. J Am Osteopath Assoc.2015;115(2):110-114. doi:10.7556/jaoa.2015.022.10.7556/jaoa.2015.022Search in Google Scholar PubMed
10. Lin CC , HuCC, HoJD, ChiuHW, LinHC. Obstructive sleep apnea and increased risk of glaucoma; a population-based matched-cohort study. Ophthalmology. 2013;120(8):1559-1564.10.1016/j.ophtha.2013.01.006Search in Google Scholar PubMed
11. Blumen Ohana E , BlumenMB, BluwolE, DerriM, ChabolleF, NordmannJP. Primary open angle glaucoma and snoring: prevalence of OSAS. Eur Ann Otorhinolaryngol Head Neck Dis.2010;127(5):159-164.10.1016/j.anorl.2010.07.003Search in Google Scholar PubMed
12. Pérez-Rico C , Gutiérrez-DíazE, Mencía-GutiérrezE, Díaz-de-AtauriM, BlancoR. Obstructive sleep apnea–hypopnea syndrome (OSAHS) and glaucomatous optic neuropathy. Graefes Arch Clin Exp Ophthalmol.2014;252(9):1345-1357. doi:10.1007/s00417-014-2669-4.10.1007/s00417-014-2669-4Search in Google Scholar PubMed
13. Emanuel ME , GeddeSJ. Indications for a systemic work-up in glaucoma. Can J Ophthalmol.2014;49(6):506-511. doi:10.1016/j.jcjo.2014.10.001.10.1016/j.jcjo.2014.10.001Search in Google Scholar PubMed
14. Muniesa M , Sánchez-de-la-TorreM, HuervaVH, LumbierresM, BarbéF. Floppy eyelid syndrome as an indicator of the presence of glaucoma in patients with obstructive sleep apnea. J Glauc.2014;23(1):e81-e85. doi:10.1097/IJG.0b013e31829da19f.10.1097/IJG.0b013e31829da19fSearch in Google Scholar PubMed
15. Pepin JL , ChiquetC, TamisierR, LevyP, AlmanjoumiA, RomanetJP. Frequent loss of nyctohemeral rhythm of intraocular pressure restored by nCPAP treatment in patients with severe apnea. Arch Ophthalmol.2010;128(10):1257-1263.10.1001/archophthalmol.2010.220Search in Google Scholar
16. Prata TS , De MoraesCG, KanadaniFN, RitchR, ParanhosAJr. Posture-induced intraocular pressure changes: considerations regarding body position in glaucoma patients. Surv Ophthalmol.2010;55(5):445-453. doi:10.1016/j.survophthal.2009.12.002.10.1016/j.survophthal.2009.12.002Search in Google Scholar
17. Campion E , BiousseV, NewmanN. Ischemic optic neuropathies. N Engl J Med.2015;372(25):2428-2436. doi:10.1056/NEJMra1413352.10.1056/NEJMra1413352Search in Google Scholar
18. Archer EL , PepinS. Obstructive sleep apnea and nonarteritic anterior ischemic optic neuropathy: evidence for an association. J Clin Sleep Med.2013;9(6):613-618. doi:10.5664/jcsm.2766.10.5664/jcsm.2766Search in Google Scholar
19. Aptel F , KhayiH, PépinJL, et al.. Association of nonarteritic ischemic optic neuropathy with obstructive sleep apnea syndrome: consequences for obstructive sleep apnea screening and treatment. JAMA Ophthalmol.2015;133(7):797-804. doi:10.1001/jamaophthalmol.2015.0893.10.1001/jamaophthalmol.2015.0893Search in Google Scholar
20. Dickersin K , LiT. Surgery for nonarteritic anterior ischemic optic neuropathy. Cochrane Database Syst Rev.2015;(3):CD001538. doi:10.1002/14651858.cd001538.pub4.10.1002/14651858.CD001538.pub4Search in Google Scholar
21. Purvin VA , KawasakiA, YeeRD. Papilledema and obstructive sleep apnea syndrome. Arch Ophthalmol.2000;118(12):1626-1630. doi:10.1001/archopht.118.12.1626.10.1001/archopht.118.12.1626Search in Google Scholar
22. Fraser CL , BliwiseDL, NewmanNJ, et al.. A prospective photographic study of the ocular fundus in obstructive sleep apnea. J Neuroophthal.2013;33(3):241-246. doi:10.1097/wno.0b013e318290194f.10.1097/WNO.0b013e318290194fSearch in Google Scholar
23. Wardly DE. Intracranial hypertension associated with obstructive sleep apnea: a discussion of potential etiologic factors. Med Hypotheses.2014;83(6):792-797. doi:10.1016/j.mehy.2014.10.011.10.1016/j.mehy.2014.10.011Search in Google Scholar
24. Johnson LN , KrohelGBMadsenRW, MarchGA. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology. 1998;105(12):2313-2317. doi:10.1016/s0161-6420(98)91234-9.10.1016/S0161-6420(98)91234-9Search in Google Scholar
25. Javaheri S , QuereshiL, GolnikK. Resolution of papilledema associated with OSA treatment. J Clin Sleep Med.2011;7(4):399-400. doi:10.5664/JCSM.1202.10.5664/JCSM.1202Search in Google Scholar PubMed PubMed Central
26. Gupta PK , StinnettSS, CarlsonAN. Prevalence of sleep apnea in patients with keratoconus. Cornea. 2012;31(6):595-599. doi:10.1097/ico.0b013e31823f8acd.10.1097/ICO.0b013e31823f8acdSearch in Google Scholar PubMed
27. Saidel MA , PaikJY, GarciaC, RussoP, CaoD, BouchardC. Prevalence of sleep apnea syndrome and high-risk characteristics among keratoconus patients. Cornea. 2012;31(6):600-603. doi:10.1097/ico.0b013e318243e446.10.1097/ICO.0b013e318243e446Search in Google Scholar PubMed
28. Pihlblad MS , SchaeferDP. Eyelid laxity, obesity, and obstructive sleep apnea in keratoconus. Cornea. 2013;32(9):1232-1236. doi:10.1097/ico.0b013e318281e755.10.1097/ICO.0b013e318281e755Search in Google Scholar PubMed
29. Gencer B , OzgurhanEB, KaraS, et al.. Obesity and obstructive sleep apnea in patients with keratoconus in a Turkish population. Cornea. 2014;33(2):137-140. doi:10.1097/ico.0000000000000024.10.1097/ICO.0000000000000024Search in Google Scholar PubMed
30. Liegl R , UlbigMW. Central serous chorioretinopathy. Ophthalmologica. 2014;232(2):65-76. doi:10.1159/000360014.10.1159/000360014Search in Google Scholar PubMed
31. Yavaş GF , KüsbeciT, KaşikciM, et al.. Obstructive sleep apnea in patients with central serous chorioretinopathy. Curr Eye Res. 2014;39(1):88-92. doi:10.3109/02713683.2013.824986.10.3109/02713683.2013.824986Search in Google Scholar PubMed
32. Brodie FL , CharlsonES, AlemanTS, et al.. Obstructive sleep apnea and central serous chorioretinopathy. Retina. 2015;35(2):238-243. doi:10.1097/iae.0000000000000326.10.1097/IAE.0000000000000326Search in Google Scholar PubMed PubMed Central
33. Mason RH , WestSD, KiireCA, et al.. High prevalence of sleep disordered breathing in patients with diabetic macular edema. Retina. 2012;34(1):1791-1798. doi:10.1097/iae.0b013e318259568b.10.1097/IAE.0b013e318259568bSearch in Google Scholar PubMed
34. Nesmith BL , IhnenM, SchaalS. Poor responders to bevacizumab pharmacotherapy in age-related macular degeneration and in diabetic macular edema demonstrate increased risk for obstructive sleep apnea. Retina. 2014;34(12):2423-2430. doi:10.1097/iae.0000000000000247.10.1097/IAE.0000000000000247Search in Google Scholar PubMed
35. Schaal S , ShermanMP, NesmithB, et al.. Untreated obstructive sleep apnea hinders response to bevacizumab in age-related macular degeneration. Retina. 2016;36(4):791-797.10.1097/IAE.0000000000000981Search in Google Scholar PubMed
© 2016 American Osteopathic Association
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.